API | calfactant

calfactant (infasurf) Report issue

Small molecule Orphan Drug ^FDA Approved ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW

Calfactant, also known as Infasurf, is an intratracheal suspension derived from the natural surfactant in calf lungs. It is used in premature infants with lung surfactant deficiency that causes infant respiratory distress syndrome (IRDS). ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
calfactant

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$57.9067 - $65.5967

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

bovactant | calfactant | calf lung surfactant extract (clse) | infasurf

Organizations (19)

Research & Development (19)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (1)

Respiratory Distress Syndrome, Newborn

Experimental Indications - Clinical Trial Phases 1-4 (4)

Acute Lung Injury (Phase 2/Phase 3)

Bronchiolitis (Phase 1)

Bronchopulmonary Dysplasia (Phase 3)

Respiratory Distress Syndrome (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 12
# of Trial Organizations: 19

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue